NEW YORK, NY / ACCESSWIRE / July 1, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CCXI Shareholders Click Here: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=17313&wire=1
ATER Shareholders Click Here: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=17313&wire=1
RKT Shareholders Click Here: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=17313&wire=1
* ADDITIONAL INFORMATION BELOW *
ChemoCentryx, Inc. (NASDAQ:CCXI)
CCXI Lawsuit on behalf of: investors who purchased November 26, 2019 - May 6, 2021
Lead Plaintiff Deadline : July 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=17313&wire=1
According to the filed complaint, during the class period, ChemoCentryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Aterian, Inc. (NASDAQ:ATER)
ATER Lawsuit on behalf of: investors who purchased December 1, 2020 - May 3, 2021
Lead Plaintiff Deadline : July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=17313&wire=1
According to the filed complaint, during the class period, Aterian, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Rocket Companies, Inc. (NYSE:RKT)
RKT Lawsuit on behalf of: investors who purchased February 25, 2021 - May 5, 2021
Lead Plaintiff Deadline : August 30, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=17313&wire=1
According to the filed complaint, during the class period, Rocket Companies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) Rocket's gain on sale margins were contracting at the highest rate in two years as a result of increased competition among mortgage lenders, an unfavorable shift toward the lower margin Partner Network operating segment and compression in the price spread between the primary and secondary mortgage markets; (b) Rocket was engaged in a price war and battle for market share with its primary competitors in the wholesale market, which was further compressing margins in Rocket's Partner Network operating segment; (c) the adverse trends identified above were accelerating and, as a result, Rocket's gain on sale margins were on track to plummet at least 140 basis points in the first six months of 2021; (d) as a result of the above, the favorable market conditions that had preceded the Class Period and allowed Rocket to achieve historically high gain on sale margins had vanished as the Company's gain on sale margins had returned to levels not seen since the first quarter of 2019; (e) rather than remaining elevated due to surging demand, Rocket's Company-wide gain-on-sale margins had fallen materially below recent historical averages; and (f) as a result of the foregoing, defendants' positive statements about the Company's business operations and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP